Page 227 - Multidisipliner Covid 19

COVID-19 Tedavi Stratejileri

77. Goldman JD, Lye DCB, Huiet DS, et al., Remdesivir for 5 or 10 Days
in Patients with Severe Covid-19. The New England Journal of Medicine.
2020. DOI: 10.1056/NEJMoa2015301.
78. Campochiaro C, Della-Torre E, Cavalli G, et al., Efficacy and Safety of
Tocilizumab in Severe COVID-19 Patients: A Single-Centre Retrospective
Cohort Study. Eur J Inter Med. 2020; 76:43-49. doi:10.1016/j.ejim.2020.
05.021.
79. Capra R, De Rossi N, Mattioli F, et al., Impact of low dose tocilizumab
on mortality rate in patients with COVID-19 related pneumonia. Eur
J Intern Med. 2020; 76:31-35. doi: 10.1016/j.ejim.2020.05.009.
80. Klopfenstein T, Zayet S, Lohse A, et al., Tocilizumab Therapy Reduced
Intensive Care Unit Admissions and/or Mortality in COVID-19 Patients.
Med Mal Infect. 2020; S0399-077X(20)30129-3. doi:10.1016/j.medmal.2020.
05.001.
81. Salazar E, Perez KK, Ashraf M, et al., Treatment of COVID-19 Patients
with Convalescent Plasma. Am J Pathol. 2020; S0002-9440(20)30257-1.
doi: 10.1016/j.ajpath.2020.05.014.
82. Li L, Zhang W, Hu Y, et al., Effect of Convalescent Plasma Therapy on
Time to Clinical Improvement in Patients With Severe and Life-threat-
ening COVID-19: A Randomized Clinical Trial. JAMA. 2020.doi:10.1001/
jama.2020.10044.
83. Liu STH, Lin HM, Baine I, et al., Convalescent plasma treatment of
severe COVID-19: A matched control study. medRxiv. 2020.doi.org/10.
1101/2020.05.20.20102236.
84. Fung TS, Liu DX. Coronavirus infection, ER stress, apoptosis and innate
immunity. Frontiers in Microbiology. 2014; 5(296): 1-13.https://doi.org/10.
3389/fmicb.2014.00296.

226